Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

2.1K
The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
2.1K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Depressive Symptoms Pre- and Post-Kidney Transplantation.

Kidney360·2026
Same author

American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.

Thyroid : official journal of the American Thyroid Association·2026
Same author

The Association Between Post-Kidney Transplant Persistent Hyperparathyroidism and Fracture Risk: A Longitudinal Cohort Study.

Clinical transplantation·2026
Same author

Which bot is best? Accuracy and readability of generative artificial intelligence assistant responses on adrenal nodules.

American journal of surgery·2026
Same author

Aldosterone Levels Post-IV Saline Suppression Using Commercial Reference Laboratory Liquid Chromatography-Tandem Mass Spectrometry Assay.

AACE endocrinology and diabetes·2026
Same author

Strengthening the Away Sub-Internship Experience: Practical Skills and Strategies for Transition to Internship.

Journal of surgical education·2026

Related Experiment Video

Updated: Jun 27, 2025

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

1.9K

Secondary Hyperparathyroidism and Cognitive Decline.

Philip Crepeau1, Tatiana Fedorova1, Lilah F Morris-Wiseman1

  • 1Department of Surgery, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 606, Baltimore, MD 21287, USA.

Current Transplantation Reports
|May 6, 2024
PubMed
Summary
This summary is machine-generated.

Secondary hyperparathyroidism (SHPT) is linked to cognitive decline in end-stage kidney disease (ESKD). Treating SHPT may reduce this risk, but more research is needed on specific cognitive impacts.

Keywords:
Chronic kidney diseaseCognitive declineDementiaEnd-stage kidney diseaseParathyroid hormoneSecondary hyperparathyroidism

More Related Videos

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.0K
Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

14.6K

Related Experiment Videos

Last Updated: Jun 27, 2025

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

1.9K
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.0K
Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

14.6K

Area of Science:

  • Nephrology
  • Neurology
  • Endocrinology

Background:

  • Secondary hyperparathyroidism (SHPT) is common in end-stage kidney disease (ESKD).
  • Cognitive decline is highly prevalent in ESKD patients.
  • SHPT is a potential contributor to cognitive impairment in ESKD.

Purpose of the Study:

  • To review recent literature on the association between SHPT and cognitive decline in ESKD.
  • To identify potential mechanisms linking SHPT and cognitive impairment.
  • To evaluate the impact of SHPT treatment on cognitive function.

Main Methods:

  • Systematic literature review of studies published in the last two decades.
  • Analysis of studies investigating the relationship between parathyroid hormone (PTH) levels and cognitive function.
  • Inclusion of studies examining brain structural changes and treatment effects.

Main Results:

  • Nine studies consistently showed an association between elevated PTH levels and cognitive decline.
  • One study reported brain structural changes related to SHPT.
  • Two studies indicated that SHPT treatment reduced the risk of cognitive decline in ESKD patients.

Conclusions:

  • SHPT is associated with cognitive impairment in ESKD.
  • The severity and specific cognitive domains affected by SHPT require further investigation.
  • Future research should explore cognitive trajectories, optimal SHPT treatments, and the role of kidney transplant.